

**UNCLASSIFIED**

**Exhibit R-2, RDT&E Budget Item Justification:** PB 2013 Army **DATE:** February 2012

<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>				<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>							
<b>COST (\$ in Millions)</b>	<b>FY 2011</b>	<b>FY 2012</b>	<b>FY 2013 Base</b>	<b>FY 2013 OCO</b>	<b>FY 2013 Total</b>	<b>FY 2014</b>	<b>FY 2015</b>	<b>FY 2016</b>	<b>FY 2017</b>	<b>Cost To Complete</b>	<b>Total Cost</b>
Total Program Element	27.247	35.543	24.384	-	24.384	20.818	20.425	21.441	21.336	Continuing	Continuing
808: <i>DOD DRUG &amp; VACC AD</i>	7.006	11.750	9.987	-	9.987	10.292	10.072	11.963	12.083	Continuing	Continuing
811: <i>MIL HIV VAC&amp;DRUG DEV</i>	2.819	2.384	2.294	-	2.294	0.904	0.884	0.845	0.859	Continuing	Continuing
836: <i>Field Medical Systems Advanced Development</i>	17.422	19.769	11.638	-	11.638	9.060	9.012	8.227	8.279	Continuing	Continuing
VS7: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV</i>	-	1.640	0.465	-	0.465	0.562	0.457	0.406	0.115	Continuing	Continuing

**A. Mission Description and Budget Item Justification**

This program element (PE) funds development of medical materiel at the start of an official program of record, within the early system integration portion of the System Development and Demonstration phase of the acquisition life cycle using 6.4 funding. Program efforts support transition of promising Science and Technology candidate medical technologies (drugs, vaccines, medical devices, diagnostics, and mechanisms for detection and control of disease carrying insects) to larger scale testing in humans for safety and effectiveness. Programs are aligned to meet Future Force (F2) requirements stressed within concept documents and organizational structures. The PE provides funding for Food and Drug Administration (FDA) regulated human clinical trials to gain additional information about safety and effectiveness on the path to licensure for use in humans. The Projects supported by this PE are:

(PROJ 836) funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project also funds the human clinical trials that test the safety and effectiveness of biologics, devices and demonstration. Clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations. Products from this project will transition to 832.

(PROJ 808) funds development of candidate medical countermeasures for infectious diseases of military relevance. Efforts include vaccines, drugs, diagnostic kits/ devices, and insect control measures. These funds support human clinical efficacy trials of the drug/vaccine in a larger group that are designed to assess performance and to continue safety assessments in a larger group of volunteers. Products from this project will transition to 849.

(PROJ 811) funds the development of military relevant human immunodeficiency virus (HIV) medical countermeasures. It provides funding for planning and conducting of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and investigate the appropriate dose for therapeutic use. Products from this project will transition to Project 812.

(PROJ VS7) program upgrades, retrofits, trains, and sustains the 256 Medical Evacuation legacy helicopters that continue to play a major role in Iraq and Afghanistan. The force design will increase the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operation needs. Products from this project will transition to VS8.

**UNCLASSIFIED**

Exhibit R-2, RDT&E Budget Item Justification: PB 2013 Army			DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY		R-1 ITEM NOMENCLATURE			
2040: Research, Development, Test & Evaluation, Army		PE 0603807A: Medical Systems - Adv Dev			
BA 4: Advanced Component Development & Prototypes (ACD&P)					
This program is managed by U.S. Army Medical Materiel Development Activity (USAMMDA) and U.S. Army Medical Materiel Agency (USAMMA) of the US Army Medical Research and Materiel Command					
B. Program Change Summary (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total
Previous President's Budget	28.132	34.997	23.291	-	23.291
Current President's Budget	27.247	35.543	24.384	-	24.384
Total Adjustments	-0.885	0.546	1.093	-	1.093
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-0.662	-			
• Adjustments to Budget Years	-	-	1.093	-	1.093
• Other Adjustments 1	-0.223	0.546	-	-	-

**UNCLASSIFIED**

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army								DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 808: DOD DRUG & VACC AD			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
808: DOD DRUG & VACC AD	7.006	11.750	9.987	-	9.987	10.292	10.072	11.963	12.083	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification											
This project funds development of candidate medical countermeasures for infectious diseases of military relevance. These efforts are in: vaccines, drugs, diagnostic kits/devices, and insect control measures. These funds support human clinical efficacy (capacity to produce a desired size of an effect under ideal or optimal conditions) trials of the drug/vaccine in larger groups that are designed to assess how well the drug/vaccine works, and to continue safety assessments in a larger group of volunteers. Funding supports both technical evaluations and human clinical testing to assure the safety and effectiveness of medical diagnostic kits and devices. This work, which is performed in military laboratories or civilian pharmaceutical firms, is directed toward the prevention of disease, early diagnosis, and speeding recovery once diagnosed. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations, a mandatory obligation for all military products placed into the hands of medical providers or service members. Product development priorities are determined based upon four major factors: (1) the extent and threat of the disease within the Combatant Commands theater of operations, (2) the clinical severity of the disease, (3) the technical maturity of the proposed solution, and (4) the affordability of the solution (development and production).											
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2011	FY 2012	FY 2013	
Title: DoD Drug and Vaccine Advanced Development								7.006	11.750	9.987	
								0	0		
Description: Funding is provided for the following effort in the development of candidate medical countermeasures for military relevant infectious disease.											
FY 2011 Accomplishments:											
Prepared to accept transition of a new military topical insect repellent from project 810 at Milestone B into Engineering & Manufacturing Development phase. If candidate was ready, transitioned new malaria vaccine candidate from project 810 into Engineering & Manufacturing Development phase. For the Infectious Disease Diagnostic (multiple candidates), prepared to accept transition of project into the Engineering & Manufacturing Development phase of advanced development. The DTV vaccine continued FDA required vaccine potency and stability testing and all other DTV activities have transitioned to project 849. For Topical Antileishmanial Cream, continued a human treatment protocol in the US, the industry partner continued stability testing of the drug product, and project 849 supported the overseas human trials activities of the topical cream.											
FY 2012 Plans:											
Review evaluations, and human clinical trials of malarial/anti-malarial drugs, vaccines, diagnostics, insect repellents, and grouped infectious disease (Dengue [a severe debilitating disease caused by a virus and transmitted by a mosquito] and Leishmania [a skin-based disease caused by a parasite and transmitted by sand flies]) vaccines, drugs and diagnostics. Seeking industry											

# UNCLASSIFIED

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2013 Army		<b>DATE:</b> February 2012	
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>	<b>PROJECT</b> 808: <i>DOD DRUG &amp; VACC AD</i>	
<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>		<b>FY 2011</b>	<b>FY 2012</b>
<p>partner and evaluating and completing down-selection of drug candidates for human trials for prevention or treatment of malaria. Continuing to evaluate the vaccine candidate for Dengue with industry partner Sanofi Pasteur. For Topical Antileishmanial Cream, continue a human treatment protocol in the US, the industry partner continues stability testing of the drug product, and project 849 supports the overseas human clinical trials activities of the topical cream.</p> <p><b><i>FY 2013 Plans:</i></b> The New Standard Military Insect Repellant testing transitioned to advanced development in FY 2011, to be funded with Defense Health Program Budget Activity 7 funding as the potential candidates are all commercially available. Will review evaluations, and data from the Phase 2 safety/efficacy clinical trials completed in FY 2012 for the Topical Antileishmanial Cream; complete preparation for Phase 3 Pivotal clinical trials for Topical Antileishmanial Cream; continue site development efforts in Cambodia and begin a Phase 3 Pivotal clinical trial for Malaria Prophylaxis with commercial partner Glaxo-Smith Kline; finalize analysis and evaluation of Phase 2 efficacy and safety data for the vaccine candidate for Dengue with industry partner Sanofi Pasteur; transition JBAIDS assay planned to advanced development and begin developmental testing; complete final process validation for Leishmania Rapid Diagnostic Device (LRDD); complete FDA approval and transition to Project 849 for Antimalarial Drug, Artesunate Intravenous.</p>			
<b>Accomplishments/Planned Programs Subtotals</b>		7.006	11.750
<b>C. Other Program Funding Summary (\$ in Millions)</b>			
N/A			
<b>D. Acquisition Strategy</b>			
Test and evaluate in-house and commercially developed products in extensive government-managed clinical trials to gather data required for FDA licensure and Environmental Protection Agency registration.			
<b>E. Performance Metrics</b>			
Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.			

## UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army										DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY				R-1 ITEM NOMENCLATURE				PROJECT					
2040: Research, Development, Test & Evaluation, Army				PE 0603807A: Medical Systems - Adv Dev				808: DOD DRUG & VACC AD					
BA 4: Advanced Component Development & Prototypes (ACD&P)													
Management Services (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Not Applicable:Not applicable	12.062	1.250		1.919		-		1.919	Continuing	Continuing	Continuing
Subtotal			12.062	1.250		1.919		-		1.919			
Product Development (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	TBD	Not applicable:Not applicable	12.509	8.269		3.080		-		3.080	Continuing	Continuing	Continuing
Product Development of Malaria Prophylaxis	TBD	Walter Reed Army Institute of Research:Silver Spring, MD	-	-		3.000		-		3.000	0.000	3.000	0.000
Subtotal			12.509	8.269		6.080		-		6.080			
Support (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Not Applicable:Not applicable	6.385	1.431		1.388		-		1.388	Continuing	Continuing	Continuing
Subtotal			6.385	1.431		1.388		-		1.388			
Test and Evaluation (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1M individually	Various	Not applicable:Not applicable	43.318	0.800		0.600		-		0.600	Continuing	Continuing	Continuing
Subtotal			43.318	0.800		0.600		-		0.600			

**UNCLASSIFIED**

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army										DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 808: DOD DRUG & VACC AD				
		Total Prior Years Cost	FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals		74.274	11.750		9.987		-		9.987			

**Remarks**

**UNCLASSIFIED**

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Army																DATE: February 2012																			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)								R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev								PROJECT 808: DOD DRUG & VACC AD																			
								FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016				FY 2017			
								1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
New Standard Military Topical Insect Repellant (MS-B)								■																											
Anti-Malarial drug candidates Product Design Review (PDR)								■																											
Leishmania Skin Test CDR												■																							
Topical Antileishmanial Cream CDR																■																			
Topical Antileishmanial Cream Phase 2 Safety Studies								■				■																							

**UNCLASSIFIED**

<b>Exhibit R-4A, RDT&amp;E Schedule Details:</b> PB 2013 Army			<b>DATE:</b> February 2012
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>	<b>PROJECT</b> 808: <i>DOD DRUG &amp; VACC AD</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
New Standard Military Topical Insect Repellant (MS-B)	2	2011	2	2011
Anti-Malarial drug candidates Product Design Review (PDR)	2	2011	2	2011
Leishmania Skin Test CDR	3	2011	3	2011
Topical Antileishmanial Cream CDR	4	2012	4	2012
Topical Antileishmanial Cream Phase 2 Safety Studies	2	2011	4	2012



**UNCLASSIFIED**

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army								DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 811: MIL HIV VAC&DRUG DEV			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
811: MIL HIV VAC&DRUG DEV	2.819	2.384	2.294	-	2.294	0.904	0.884	0.845	0.859	Continuing	Continuing
Quantity of RDT&E Articles											
A. Mission Description and Budget Item Justification											
This project funds development of militarily relevant human immunodeficiency virus (HIV) medical countermeasures. It provides funding for the planning and conducting of human clinical trials in a group of healthy volunteers to assess the drug/vaccine for safety, tolerability, how the drug/vaccine is distributed, metabolized, and excreted from the body, and to investigate the appropriate dose for therapeutic use. Development efforts are focused on militarily unique needs effecting manning, mobilization, and deployment.											
The major contractor is Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD. Research efforts are coordinated with the National Institutes of Health.											
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2011	FY 2012	FY 2013	
Title: Military HIV Vaccine & Drug Development  Articles:  Description: This project funds advanced development research to develop candidate HIV vaccines, assess their safety and effectiveness in evaluations with human subjects, and protect military personnel from risks associated with HIV infection.  FY 2011 Accomplishments: Sought new industry partnership for selected candidate(s) drug/vaccine for HIV medical treatment/prevention.  FY 2012 Plans: Perform three inter-related studies to enhance our understanding of precisely how the vaccine strategy used in the 2009 safety/ efficacy trial caused vaccine recipients to be protected from infection, including intense laboratory studies using samples from the trial, and commencement of two small clinical vaccine trials to generate data and samples to define what vaccine responses to try to generate for next increment studies.  FY 2013 Plans: Will complete three inter-related previous clinical trials aimed at refining our understanding of immune responses elicited by the increment 1 HIV vaccine strategy. Analyze laboratory interrogation of samples from trial participants.								2.819	2.384	2.294	
								0	0		
Accomplishments/Planned Programs Subtotals								2.819	2.384	2.294	

**UNCLASSIFIED**

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2013 Army		<b>DATE:</b> February 2012
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>	<b>PROJECT</b> 811: <i>MIL HIV VAC&amp;DRUG DEV</i>
<b>C. Other Program Funding Summary (\$ in Millions)</b> N/A		
<b>D. Acquisition Strategy</b> Test and evaluate commercially developed drug/vaccine candidates in government-managed trials.		
<b>E. Performance Metrics</b> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.		

**UNCLASSIFIED**

<b>Exhibit R-3, RDT&amp;E Project Cost Analysis:</b> PB 2013 Army											<b>DATE:</b> February 2012		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: Medical Systems - Adv Dev				<b>PROJECT</b> 811: MIL HIV VAC&DRUG DEV					

  

<b>Management Services (\$ in Millions)</b>				<b>FY 2012</b>		<b>FY 2013 Base</b>		<b>FY 2013 OCO</b>		<b>FY 2013 Total</b>			
<b>Cost Category Item</b>	<b>Contract Method &amp; Type</b>	<b>Performing Activity &amp; Location</b>	<b>Total Prior Years Cost</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
No product/contract costs greater than \$1M individually.	TBD	Not Applicable:Not Applicable	1.135	0.473		0.456		-		0.456	Continuing	Continuing	Continuing
<b>Subtotal</b>			1.135	0.473		0.456		-		0.456			

  

<b>Remarks</b> Not Applicable													
----------------------------------	--	--	--	--	--	--	--	--	--	--	--	--	--

  

<b>Product Development (\$ in Millions)</b>				<b>FY 2012</b>		<b>FY 2013 Base</b>		<b>FY 2013 OCO</b>		<b>FY 2013 Total</b>			
<b>Cost Category Item</b>	<b>Contract Method &amp; Type</b>	<b>Performing Activity &amp; Location</b>	<b>Total Prior Years Cost</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
No product/contract costs greater than \$1M individually	TBD	Not applicable:Not applicable	2.258	0.360		0.574		-		0.574	Continuing	Continuing	Continuing
<b>Subtotal</b>			2.258	0.360		0.574		-		0.574			

  

<b>Support (\$ in Millions)</b>				<b>FY 2012</b>		<b>FY 2013 Base</b>		<b>FY 2013 OCO</b>		<b>FY 2013 Total</b>			
<b>Cost Category Item</b>	<b>Contract Method &amp; Type</b>	<b>Performing Activity &amp; Location</b>	<b>Total Prior Years Cost</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
No product/contract costs greater than \$1 Million individually	TBD	TBD:TBD	0.493	0.444		0.534		-		0.534	0.000	1.471	0.000
<b>Subtotal</b>			0.493	0.444		0.534		-		0.534	0.000	1.471	0.000

  

<b>Remarks</b> Not Applicable													
----------------------------------	--	--	--	--	--	--	--	--	--	--	--	--	--

**UNCLASSIFIED**

<b>Exhibit R-3, RDT&amp;E Project Cost Analysis:</b> PB 2013 Army											<b>DATE:</b> February 2012			
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>				<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>				<b>PROJECT</b> 811: <i>MIL HIV VAC&amp;DRUG DEV</i>						

  

<b>Test and Evaluation (\$ in Millions)</b>				<b>FY 2012</b>		<b>FY 2013 Base</b>		<b>FY 2013 OCO</b>		<b>FY 2013 Total</b>			
<b>Cost Category Item</b>	<b>Contract Method &amp; Type</b>	<b>Performing Activity &amp; Location</b>	<b>Total Prior Years Cost</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
No product/contract costs greater than \$1M individually	TBD	Not applicable:Not Applicable	14.012	1.107		0.730		-		0.730	0.000	15.849	0.000
<b>Subtotal</b>			14.012	1.107		0.730		-		0.730	0.000	15.849	0.000

  

<b>Remarks</b> Not Applicable													
----------------------------------	--	--	--	--	--	--	--	--	--	--	--	--	--

  

	<b>Total Prior Years Cost</b>	<b>FY 2012</b>		<b>FY 2013 Base</b>		<b>FY 2013 OCO</b>		<b>FY 2013 Total</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
<b>Project Cost Totals</b>	17.898	2.384		2.294		-		2.294			

  

<b>Remarks</b>											
----------------	--	--	--	--	--	--	--	--	--	--	--

**UNCLASSIFIED**

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Army																				DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)										R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev										PROJECT 811: MIL HIV VAC&DRUG DEV			

**UNCLASSIFIED**

<b>Exhibit R-4A, RDT&amp;E Schedule Details:</b> PB 2013 Army			<b>DATE:</b> February 2012
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>	<b>PROJECT</b> 811: <i>MIL HIV VAC&amp;DRUG DEV</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
RV305 Phase 2 Study of Secondary Boost	2	2011	4	2013
RV306 Phase 2 Study	2	2011	4	2013
RV328 Phase 2 Study of AIDSVAXB/E	1	2012	4	2014
Prime/Boost Phase 3 Study	1	2015	4	2016

**UNCLASSIFIED**

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army									DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 836: Field Medical Systems Advanced Development			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
836: Field Medical Systems Advanced Development	17.422	19.769	11.638	-	11.638	9.060	9.012	8.227	8.279	Continuing	Continuing
Quantity of RDT&E Articles											

**Note**

Not applicable for this PE.

**A. Mission Description and Budget Item Justification**

This project funds the demonstration and validation of medical products for enhanced combat casualty care and follow-on care, including rehabilitation. This project funds human clinical trials to test the safety and effectiveness of biologics (products derived from living organisms) and devices necessary to meet medical requirements. When available, commercial-off-the-shelf (COTS) medical products are also tested and evaluated for transition to system development and demonstration. Consideration is also given to reducing the medical logistics footprint through smaller weight, volume, and equipment independence from supporting materials. All clinical trials are conducted in accordance with U.S. Food and Drug Administration (FDA) regulations.

Major contractors/intra-governmental agencies include: IGR Enterprises, Inc.; Army Medical Department Board Test Center; SeQual Technologies, Inc.; Ultrasonic Diagnostics, Inc.; HemCon Medical Technologies, Inc.; Hemerus Medical, LLC.; Fast Track Drugs & Biologics, LLC; Clinical Research Management, and Walter Reed Army Institute of Research (WRAIR) and Institute of Surgical Research (ISR) for user evaluation. Other military agencies include Program Executive Office (PEO) Soldier, PEO Combat Service Support, and Naval Undersea Warfare Center.

**B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)**

	<b>FY 2011</b>	<b>FY 2012</b>	<b>FY 2013</b>
<b>Title:</b> Field Medical Systems Advanced Development	17.422	-	-
<b>Articles:</b>	0		
<b>Description:</b> Funding is provided for demonstration and validation of medical products for enhanced casualty care and follow-on care, including rehabilitation.			
<b>FY 2011 Accomplishments:</b> Total Intravenous Anesthesia (TIVA): Performed clinical trials and submitted required documents for FDA clearance/approval. Auto Critical Care System (ACCLS): Conducted validation testing and Army DT/OT/AWC. Submitted the 510K for FDA review for modified devices. Urinary Facilitation Device: Tested, reported, and reviewed for FDA approval. PEAK Surgical System (Plasma Blade): preclinical results were favorable, conducted environmental testing and identified any needed design modifications to produce a fieldable unit. Pursued additional regulatory approvals as needed. Plasma Knife: preclinical results were favorable, conducted environmental testing and identified design modifications to produce a fieldable unit. Pursued additional regulatory approvals as needed. Hydrosurgery System: Conducted operational and environmental testing. Remote Diagnostic Access (RDA): Developed software, conduct testing, and refinement for MOC Sensor Modular Development phase. Treatment Table for			

# UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army			DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)		R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev	PROJECT 836: Field Medical Systems Advanced Development		
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)			FY 2011	FY 2012	FY 2013
PM, HBCT Medical Mission Package for Treatment Variants: Transitioned to Project 832. Refrigerator for PM, HBCT for Medical Mission Package for Treatment Variant: Transitioned to Project 832. Shock and Vibration Isolation System for Patient Litters in Ground and Air Medical Evacuation Vehicles: Transitioned to Project 832. Shelter for PM, HBCT for Medical Mission Package for Treatment Variant: Transitioned to Project 832. Passive Cold Chain Capability for Temperature Sensitive Medical Materiel: Transitioned to Project 832. The intranasal ketamine drug effects study transitioned to project 832 for Systems Development and Demonstration.					
Title: Field Medical Systems Advanced Development - PM Medical Devices  Articles:  Description: Advanced development funding is provided for the following development of medical devices in support of enhanced combat casualty care.  FY 2012 Plans: Non-invasive Multi-Analyte Monitor: submit RFP for the use of Infra Red Spectrometry to assess analyte concentration in blood. Hydration Meter: Conduct validation testing. Plasma Knife: Transition product to Project 832. Eye Tracking System for assessing concussions is a traumatic brain injury diagnostic tool that begins clinical trial to move to FDA submission. Fibrinogen Bandages will use an antimicrobial irrigation solution to protect blast injury wound sites from bacterial infection. Conduct final review of Good Manufacturing Practice (GMP) for movement forward to FDA submission. Cardiopulmonary Enhancement: Conduct multiple collaborative clinical protocols to review arrest and life threatening trauma devices for enhanced treatment.  FY 2013 Plans: Total Intravenous Anesthesia (TIVA): This product will transition to Tech Watch in FY 2012 and is not scheduled for further development in FY 2013. Auto Critical Care System (ACCLS): Program is cancelled as it is no longer a viable product. Urinary Facilitation Device: No further R&D funding required as this is now a commercial product. PEAK Plasmablade: No further R&D funding required as this is now a commercial product. Hydrosurgery System: No further R&D funding required as this is now a commercial product. Non-invasive Multi-Analyte Monitor: submission cancelled because the Small Business innovation Research (SBIR) Product failed to meet future need/requirement. Eye Tracking System for Assessing Concussions (system is a traumatic brain injury diagnostic tool): IPT for Smooth Pursuit Eye Tracking will rebaseline plan in January 2012 for next steps to reach MSB in FY 2013-FY 2014. Fibrinogen Bandages: Phase I clinical trial is scheduled to begin in FY 2013. No further funding is planned after current contract. Product is a biologic and is transitioning back to S&T. Cardiopulmonary Enhancement: Currently there is no device requirement identified. Bandits Banyan Biomarkers (now called TBI Diagnostic Assay System _ Increment II and Increment III Handheld): Enrollment for clinical trials continues and will identify a handheld platform for independent testing in June 2012. Will schedule Milestone B review.			-	7.428 0	6.480
Title: Field Medical Systems Advanced Development - PM Pharmaceuticals			-	8.063	2.486



**UNCLASSIFIED**

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army		DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)	R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev	PROJECT 836: Field Medical Systems Advanced Development		
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)		FY 2011	FY 2012	FY 2013
<div>Articles:</div> <p>Description: Funding is provided for advanced development of biologic medical products managed by PM Pharmaceuticals.</p> <p>FY 2012 Plans: Cryopreserved Platelets formerly Platelet Derived Hemostatic Agent (use of cryopreserved platelets for control of severe bleeding): Conduct clinical safety evaluations and conduct good manufacturing practices preliminary validation studies of the product. The Freeze-Dried Plasma Program (hemorrhage treatment candidate): Conduct preliminary clinical evaluations and conduct good manufacturing practices preliminary validation studies.</p> <p>FY 2013 Plans: Blood Pathogen Reduction/Inactivation transitioned to advanced development in FY 2012, transitioning from Army to be funded with Defense Health Program RDT&amp;E funding; transitioned to Freeze-dried Plasma program to maintain current schedule and avoid delays Conduct Milestone B decision reviews for both Cryopreserved Platelets and Freeze-Dried Plasma Programs (New high priority from DoD leadership). Accelerated fielding of a FDA-approved Freeze-Dried Plasma was validated in the June 2011 Army Surgeon General's Report by the Blast Injury Task Force. Cryopreserved Platelets: Start Phase 2 safety/efficacy clinical trial in cancer patients with platelet deficiency. Freeze-Dried Plasma program: Complete Phase 2 clinical trial of safety and efficacy through a Cooperative Agreement with industry partner.</p>			0	
<div>Articles:</div> <p>Title: Field Medical systems Advanced Development - PM Integrated Clinical Systems (ICS)</p> <p>Description: Funding is provided for the following effort for medical products managed by PM ICS.</p> <p>FY 2012 Plans: Conduct final testing of Phase IV of the Remote Diagnostic Access (RDA). Develop a universal security compliant access portal to serve as a standardized compliance wrapper for all vendors, medical technology, and even IT management products that may traverse between the .com and .mil networks. The Milestone Decision Authority (MDA) is scheduled to review the RDA project in 2011 for continuation of development or termination due to commercial availability.</p>		-	0.888 0	-
<div>Articles:</div> <p>Title: Field Medical Systems Advanced Development - PM Medical Support Systems</p> <p>Description: Funding is provided for the following effort in the development of products that support the medical mission in combat casualty care and health care operations.</p> <p>FY 2012 Plans:</p>		-	3.390 0	2.672

# UNCLASSIFIED

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2013 Army		<b>DATE:</b> February 2012	
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>	<b>PROJECT</b> 836: <i>Field Medical Systems Advanced Development</i>	
<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>		<b>FY 2011</b>	<b>FY 2012</b>
<p>Prepare and complete testing of the Treatment Table and Blood Refrigerator prototypes for PM HBCT. Shock and Vibration Litter Isolation project terminated by MDA. Test new cold chain technologies for MES set inclusion. Prototype evaluation of Quad fold litter, litter straps, and hands-free litter system: Test new ISO shelter panel and transition back into ISO shelter specification for future shelter buys. Test Trauma Tiered Medical Bag and transition to PEO soldier. Continue to finalize soft-walled shelter development for Force Provider modules for use in Combat Support Hospitals. Develop and transition prototype Water and Waste Water Management system to Project 832 for further development.</p> <p><b>FY 2013 Plans:</b> Will transition treatment table and blood refrigerator for PM HBCT to Project 832 and continue development. Will transition advanced cold chain technologies, trauma tiered medical bag, hoist aeromedical evacuation litter, and quad fold litter to Project 832 and continue development. Will transition ISO panel development and Force Provider soft walled module components to 832 to finalize development. Will develop prototype for Environmental Sentinel Biomonitor, which transitioned from Science &amp; Technology. Will apply funding from Milestone Decision Authority terminated project Shock and Vibration Litter System to a SBIR Phase II product, insecticide impregnated bed net, and acquire data for EPA approval. Will collaborate with PEO Combat Service Support on development efforts for emerging medical vehicle evacuation variants.</p>			
<b>Accomplishments/Planned Programs Subtotals</b>		17.422	19.769
<b>C. Other Program Funding Summary (\$ in Millions)</b>			
N/A			
<b>D. Acquisition Strategy</b>			
Develop in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding.			
<b>E. Performance Metrics</b>			
Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.			

**UNCLASSIFIED**

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army										DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT 836: Field Medical Systems Advanced Development					
Management Services (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$M individually.	Various	Not Applicable:Not applicable	37.279	2.540		0.622		-		0.622	Continuing	Continuing	Continuing
Subtotal			37.279	2.540		0.622		-		0.622			
Product Development (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Product Development	TBD	Clinical Research Management:Hinckley, Ohio	1.133	-		-		-		-	Continuing	Continuing	Continuing
Product Development	TBD	Allied Technologies & Consulting LLC:Frederick, MD	6.945	-		-		-		-	Continuing	Continuing	Continuing
Product Development	TBD	Banyan BioMarkers, Inc:Alachua FL	27.000	-		5.050		-		5.050	Continuing	Continuing	Continuing
Product Development	TBD	HemCon Medical Technologies:Tigard, Oregon	1.520	8.000		-		-		-	Continuing	Continuing	Continuing
Development of Platelet Derived Hemostatic agent	TBD	Fast Track Drugs & Biologics:Frederick, MD	-	1.500		-		-		-	Continuing	Continuing	Continuing
Product Development	TBD	Aquila Alaska Corporation:Aquila Alaska	1.200	-		-		-		-	Continuing	Continuing	Continuing
Product Development	TBD	ALL Product:Various	1.000	1.000		-		-		-	Continuing	Continuing	Continuing
Product Development of Freeze-dried plasma	TBD	TBD:TBD	-	-		2.400		-		2.400	Continuing	Continuing	Continuing
Product Development	TBD	Not Applicable:Not Applicable	26.067	-		-		-		-	Continuing	Continuing	Continuing
Subtotal			64.865	10.500		7.450		-		7.450			

**UNCLASSIFIED**

<b>Exhibit R-3, RDT&amp;E Project Cost Analysis:</b> PB 2013 Army											<b>DATE:</b> February 2012		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>				<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>				<b>PROJECT</b> 836: <i>Field Medical Systems Advanced Development</i>					
<b>Support (\$ in Millions)</b>				<b>FY 2012</b>		<b>FY 2013 Base</b>		<b>FY 2013 OCO</b>		<b>FY 2013 Total</b>			
<b>Cost Category Item</b>	<b>Contract Method &amp; Type</b>	<b>Performing Activity &amp; Location</b>	<b>Total Prior Years Cost</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
No product/contract costs greater than \$M individually.	Various	Not Applicable:Not applicable	41.747	1.273		1.066		-		1.066	Continuing	Continuing	Continuing
<b>Subtotal</b>			41.747	1.273		1.066		-		1.066			
<b>Remarks</b> No product/contract costs greater than \$1M individually.													
<b>Test and Evaluation (\$ in Millions)</b>				<b>FY 2012</b>		<b>FY 2013 Base</b>		<b>FY 2013 OCO</b>		<b>FY 2013 Total</b>			
<b>Cost Category Item</b>	<b>Contract Method &amp; Type</b>	<b>Performing Activity &amp; Location</b>	<b>Total Prior Years Cost</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Award Date</b>	<b>Cost</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
No product/contract costs greater than \$1 Million individually.	C/UCA	Not applicable:Not applicable	28.778	5.456		2.500		-		2.500	Continuing	Continuing	Continuing
<b>Subtotal</b>			28.778	5.456		2.500		-		2.500			
<b>Remarks</b> No product/contract costs greater than \$1M individually.													
			<b>Total Prior Years Cost</b>	<b>FY 2012</b>		<b>FY 2013 Base</b>		<b>FY 2013 OCO</b>		<b>FY 2013 Total</b>	<b>Cost To Complete</b>	<b>Total Cost</b>	<b>Target Value of Contract</b>
<b>Project Cost Totals</b>			172.669	19.769		11.638		-		11.638			
<b>Remarks</b>													

**UNCLASSIFIED**

Exhibit R-4, RDT&E Schedule Profile: PB 2013 Army																DATE: February 2012																			
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)								R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev								PROJECT 836: Field Medical Systems Advanced Development																			
								FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016				FY 2017			
								1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4				
Total intravenous Anesthesia (TIVA): Clinical Trials																																			
Cryopreserved Platelets Critical Design Review MS-B																																			
Freeze-Dried Plasma																																			
Non-invasive Multi-Analyte Monitor																																			
Eye Tracking System for Assessment of Concussions																																			
Remote Diagnostic Device Commercial Product Review																																			

**UNCLASSIFIED**

<b>Exhibit R-4A, RDT&amp;E Schedule Details:</b> PB 2013 Army			<b>DATE:</b> February 2012
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>	<b>PROJECT</b> 836: <i>Field Medical Systems Advanced Development</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
Total intravenous Anesthesia (TIVA): Clinical Trials	4	2011	4	2011
Cryopreserved Platelets Critical Design Review MS-B	4	2011	1	2012
Freeze-Dried Plasma	2	2012	2	2012
Non-invasive Multi-Analyte Monitor	2	2012	2	2012
Eye Tracking System for Assessment of Concussions	1	2012	1	2012
Remote Diagnostic Device Commercial Product Review	2	2011	2	2011

**UNCLASSIFIED**

Exhibit R-2A, RDT&E Project Justification: PB 2013 Army									DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT VS7: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV			
COST (\$ in Millions)	FY 2011	FY 2012	FY 2013 Base	FY 2013 OCO	FY 2013 Total	FY 2014	FY 2015	FY 2016	FY 2017	Cost To Complete	Total Cost
VS7: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV	-	1.640	0.465	-	0.465	0.562	0.457	0.406	0.115	Continuing	Continuing
Quantity of RDT&E Articles											

**A. Mission Description and Budget Item Justification**

Original models of Army Black Hawk MEDEVAC helicopters continue to play a major role in maintaining high US troop survival rates in Iraq and Afghanistan by evacuating wounded troops in less than one-hour. In 2009 a VCSA-approved force design update increased the number of air frames in the force from 12 to 15 aircraft for 37 MEDEVAC companies to better meet operational needs. In 2010, the AMEDD accepted life-cycle management of the MEDEVAC MEP from PEO Aviation. In order to achieve required operational capability and enhance commonality across the MEDEVAC fleet, the MEDEVAC MEP program upgrades, retrofits, trains, and sustains the 256 MEDEVAC legacy helicopters to achieve the medical capability provided by the HH-60M, which is factory built for the MEDEVAC mission.

**B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)**

	<b>FY 2011</b>	<b>FY 2012</b>	<b>FY 2013</b>
<b>Title:</b> MEDEVAC Mission Sensor Foward Looking Infrared (FLIR)  <b>Articles:</b>  <b>Description:</b> Funding is provided for the following effort in the advanced development of critical components in MEDEVAC MEP.  <b>FY 2012 Plans:</b> MEDEVAC Mission Sensor (MMS) FLIR for UH-60 aircraft. One of the requirements for the UH-60A/L MEDEVAC is a sensor system that will assist the pilots in locating patient pick-up points and assist them in maintaining situational awareness in night and adverse weather conditions. The MMS is currently being qualified for use on the HH-60M aircraft. This system will be installed on UH-60 aircraft using the proven Sponson-Mount FLIR system, which is currently being used in OEF for the MEDEVAC mission. The funds will develop and test a Medical Mission Sensor FLIR prototype on the UH-60A/L.	-	0.575 0	-
<b>Title:</b> Environmental Control System for MEDEVAC aircraft  <b>Articles:</b>  <b>Description:</b> Funding is provided for the following effort  <b>FY 2012 Plans:</b> The HH-60A/L/M has an environmental control system to assist in regulating the cabin temperature. This system will help prevent injury and loss of life to patients due to heat stress or hypothermia during transport. The system will also provide improved crew	-	0.509 0	-

# UNCLASSIFIED

<b>Exhibit R-2A, RDT&amp;E Project Justification:</b> PB 2013 Army		<b>DATE:</b> February 2012	
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>		<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>	<b>PROJECT</b> VST: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV</i>
<b>B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)</b>		<b>FY 2011</b>	<b>FY 2012</b>
comfort in extreme environmental conditions, particularly high temperatures. The system will utilize the component-qualified 2-Pallet ECS developed for the HH-60M and develop and test a prototype installation for the UH-60A/L.			
<b>Title:</b> Telemedicine for MEDEVAC aircraft  <b>Description:</b> Effort is focused on requirement to provide enroute patient data to treatment facilities.  <b>FY 2012 Plans:</b> Telemedicine is an ongoing requirement for US Army MEDEVAC, to allow the patient care-giver at point of injury or during transport to access the knowledge and expertise of a more qualified care-giver at a remote location, and to provide patient data to the receiving facility prior to patient arrival, allowing the facility more time to prepare for intensive care patients. The program develops, installs, and tests a telemedicine system for the UH-60A/L family of aircraft.  <b>FY 2013 Plans:</b> Will continue design, develop, and test telemedicine systems in order to provide medics with state of the art capability to monitor and communicate patient data to ground crews at forward treatment facility		<b>Articles:</b>  -  0	0.556  0.465
<b>Accomplishments/Planned Programs Subtotals</b>		-	1.640
<b>C. Other Program Funding Summary (\$ in Millions)</b> N/A			
<b>D. Acquisition Strategy</b> Develop in-house or industrial prototypes in government-managed programs to meet military MEDEVAC and regulatory requirements for production and fielding.			
<b>E. Performance Metrics</b> Performance metrics used in the preparation of this justification material may be found in the FY 2010 Army Performance Budget Justification Book, dated May 2010.			



**UNCLASSIFIED**

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army										DATE: February 2012			
APPROPRIATION/BUDGET ACTIVITY				R-1 ITEM NOMENCLATURE				PROJECT					
2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				PE 0603807A: Medical Systems - Adv Dev				VST: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV					
Management Services (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1 Million individually	TBD	APM MEDEVAC:Huntsville, AL	-	0.201		0.037		-		0.037	0.000	0.238	0.000
Subtotal			-	0.201		0.037		-		0.037	0.000	0.238	0.000
Product Development (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1Million individually	TBD	APM MEDEVAC PEO Aviation:Huntsville AL	-	1.140		0.428		-		0.428	0.000	1.568	0.000
Subtotal			-	1.140		0.428		-		0.428	0.000	1.568	0.000
Support (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1Million individually	TBD	APM MEDEVAC:Huntsville, AL	-	0.100		-		-		-	0.000	0.100	0.000
Subtotal			-	0.100		-		-		-	0.000	0.100	0.000
Test and Evaluation (\$ in Millions)				FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Total Prior Years Cost	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
No product/contract costs greater than \$1Million individually	MIPR	APM MEDEVAC PEO Aviation:Huntsville, AL	-	0.199		-		-		-	0.000	0.199	0.000
Subtotal			-	0.199		-		-		-	0.000	0.199	0.000

**UNCLASSIFIED**

Exhibit R-3, RDT&E Project Cost Analysis: PB 2013 Army									DATE: February 2012		
APPROPRIATION/BUDGET ACTIVITY 2040: Research, Development, Test & Evaluation, Army BA 4: Advanced Component Development & Prototypes (ACD&P)				R-1 ITEM NOMENCLATURE PE 0603807A: Medical Systems - Adv Dev				PROJECT VST: MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV			
	Total Prior Years Cost	FY 2012		FY 2013 Base		FY 2013 OCO		FY 2013 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	-	1.640		0.465		-		0.465	0.000	2.105	0.000

Remarks

**UNCLASSIFIED**

<b>Exhibit R-4, RDT&amp;E Schedule Profile:</b> PB 2013 Army			<b>DATE:</b> February 2012		
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>			<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>		
			<b>PROJECT</b> VST: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV</i>		

	FY 2011				FY 2012				FY 2013				FY 2014				FY 2015				FY 2016				FY 2017			
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
MEDEVAC Mission Sensor (MMS) FLIR																												
Environmental Control System																												
Telemedicine Research and Development																												

**UNCLASSIFIED**

<b>Exhibit R-4A, RDT&amp;E Schedule Details:</b> PB 2013 Army			<b>DATE:</b> February 2012
<b>APPROPRIATION/BUDGET ACTIVITY</b> 2040: <i>Research, Development, Test &amp; Evaluation, Army</i> BA 4: <i>Advanced Component Development &amp; Prototypes (ACD&amp;P)</i>	<b>R-1 ITEM NOMENCLATURE</b> PE 0603807A: <i>Medical Systems - Adv Dev</i>	<b>PROJECT</b> VST: <i>MEDEVAC MISSION EQUIPMENT PACKAGE (MEP) - ADV DEV</i>	

Schedule Details

Events	Start		End	
	Quarter	Year	Quarter	Year
MEDEVAC Mission Sensor (MMS) FLIR	1	2012	4	2012
Environmental Control System	1	2012	4	2012
Telemedicine Research and Development	1	2012	2	2017